Doxil in breast cancer

被引：13

作者：

Muggia, FM ^{[1
]}

机构：

[1] NYU Med Ctr, New York, NY 10016 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1998年 / 16卷 / 02期

关键词：

D O I：

10.1200/JCO.1998.16.2.811

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：811 / 811

页数：1

共 5 条

[1]

COATES A, 1987, NEW ENGL J MED, V317, P1494

[2] Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation [J].

Muggia, FM ;

Hainsworth, JD ;

Jeffers, S ;

Miller, P ;

Groshen, S ;

Tan, M ;

Roman, L ;

Uziely, B ;

Muderspach, L ;

Garcia, A ;

Burnett, A ;

Greco, FA ;

Morrow, CP ;

Paradiso, LJ ;

Liang, LJ .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :987-993

[3] INTERRUPTED VERSUS CONTINUOUS CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER [J].

MUSS, HB ;

CASE, LD ;

RICHARDS, F ;

WHITE, DR ;

COOPER, R ;

CRUZ, JM ;

POWELL, BL ;

SPURR, CL ;

CAPIZZI, RL .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (19) :1342-1348

[4] Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial [J].

Ranson, MR ;

Carmichael, J ;

OByrne, K ;

Stewart, S ;

Smith, D ;

Howell, A .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) :3185-3191

[5] LIPOSOMAL DOXORUBICIN - ANTITUMOR-ACTIVITY AND UNIQUE TOXICITIES DURING 2 COMPLEMENTARY PHASE-I STUDIES [J].

UZIELY, B ;

JEFFERS, S ;

ISACSON, R ;

KUTSCH, K ;

WEITSAO, D ;

YEHOSHUA, Z ;

LIBSON, E ;

MUGGIA, FM ;

GABIZON, A .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1777-1785

← 1 →